Silence sets up SAB to strengthen liver pipeline
This article was originally published in Scrip
RNA interference company Silence Therapeutics has created a scientific advisory board with the appointment of two key opinion leaders in the area of liver diseases, Professors Detlef Schuppan and Massimo Pinzani. Professor Schuppan is a consultant gastroenterologist and hepatologist, director of molecular and translational medicine, and full professor of medicine at Mainz University Medical Centre in Germany. He is also professor of medicine and senior visiting scientist at Harvard Medical School. Professor Pinzani is professor of medicine and gastroenterology at the University of Florence, Italy, and visiting professor in the division of hepatology at Osaka City School of Medicine in Japan.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.